Parathyroidectomy in Secondary (Renal) Hyperparathyroidism - Whom,When,How?

Stanbury S.W. , Lumb C.A. , Nicholson W.F. Elective subtotal parathyroidectomy for renal hyperparathyroidism. Lancet 1960; 1: 793.

Slatopolsky E. , Weerts C. , Thielan J. , Horst R. , Harter H. , Martin K.J. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25 dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136–43.

Rothmund M. , ed. Hyperparathyroidism. Thiéme, 1991.

Naveh-Many T. , Marx R. , Keshet E. , Pike J.W. , Silver J. Regulation of 1,25-dihydroxyvitamin D₃ receptor gene expression by 1,25-dihydroxyvitamin D₃ in the parathyroid in vivo. J Clin Invest 1990; 86: 1968–75.

Szabò A. , Merke J. , Beier E. , Mall G. , Ritz E. 1,25-dihydroxyvitamin D₃ inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049–56.

Brumbaugh P.F. , Hugues M.R. , Haussler M.R. Cytoplasmic and nuclear binding components for 1,25-dihydroxyvi-tamin D₃ in chick parathyroid glands. Proc Natl Acad Sci USA 1975; 72: 4871.

Mendes V. , Jorgetti V. , Nemeth J. Secondary hyperparathyroidism in chronic haemodialysis patients: a clinico-pathologic study. Proceedings of the European Dialysis and Transplant Association 1983; 20: 731–8.

Gordon R. , Strowasser M. , Martin N. , Klemm S. , Tunny T. Abnormal karyotype of adrenal cortical adenoma in familial hyperaldosteronism type II. J Hypertension 1992; 10: 14.

Beevers D.G. , Brown J.J. , Ferriss J.B. Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism. Quarterly Journal of Medicine, New Series 1976; 179: 401–10.

Fujii Y. , Moreira J.E. , Orlando C. Endothelin as an autocrine factor in the regulation of parathyroid cells. Proc Natl Acad Sci 1991; 88: 4235–9.

Koyama H. , Tabata T. , Nishizawa Y. , Inoue T. , Morii H. , Yamaji T. Plasma endothelin levels in patients with uremia. Lancet 1989; 1: 991–2.

Parfitt A.M. Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Mineral and Electrolyte Metab 1982; 8: 92–112.

Fukagawa M. , Okazaki R. , Takano K. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on longterm dialysis. N Engl J Med 1990; 323: 421–2.

Fischer E.R. , Harris D.C.H. Comparison of intermittent oral and intravenous calcitriol in hemodialisis patients with secondary hyperparathyrodism. Presented at the 28th Annual Meeting Australian/New Zealand Soc Nephrol, February 26-28, 1992.

Fournier A. , Drücke T. , Morinière Ph , Zingraff J. , Bou-daillez B. , Achard J.M. Nouveaux traitements de I'hyper-parathyreoidie de I'insuffisance rénal. In: Actualités Néphrologiques. Jean Hamburger; Médecine-Sciences, Paris: Flammarion, 1991; 233–300.

Reichel H. , Drüeke T. , Ritz E. Bony complications in chronic renal failure. In: Cameron S. , Davison M. , Grünfeld J.P. , Kerr D. , Ritz E. , eds. Oxford textbook clinical nephrology. Oxford: Med Public, 1992; 1365–89.

Reichel H. , Szabo A. , Uhl J. , Ritz E. Intermittent versus continuous administration of calcitriol: comparison of efficacy. Nephrol Dial Transplant 1992; 7: 762.

Tsukamoto Y. , Nomura M. , Takahashi Y. The oral 1,25-dihydroxyvitamin D₃ pulse therapy in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1991; 57: 23–8.

Klaus G. , Mehls O. , Hinderer J. , Ritz E. Is intermittent oral calcitriol safe and effective in renal secondary hyperparathyroidism? Lancet 1991; 337: 800–1.

Seidel A. , Paul H. , Klaus G. , Mehls O. , Schmidt-Gayk H. , Ritz E. Kinetics of plasma 1,84 iPTH after high dose of calcitriol in uremic patients. Clin Nephrol (in press).

Reichel H. , Szabò A. , Pesian S. Intermittent versus continuous administration of 1,25 (OH) ₂ D ₃. Comparison of efficiency. 25th Annual Meeting of the American Society of Nephrology, 1992; 15–8.

Kwan J.T.C. , Almond M.K. , Beer J.C. , Noonan K. , Cunningham J. Direct inhibitory effect of calcitriol in hemodialysis patients. 6th International Congress on Nutrition and Metabolism in Renal Disease. Harrogate, 1991; 26–30.

Rodriguez M. , Martin-Malo A. , Martinez M. , Felsenfeld A. , Flach F. The effect of dietary phosphorus on calcitriol levels in normal and renal failure rats. 8th Workshop on Vitamin D, Paris 1991; 5–10.

Kitaoka M. , Fukagawa M. , Tanaka Y. , Ogata E. , Kurokawa K. Parathyroid gland size is critical for longterm prognosis of calcitriol pulse therapy in chronic dialysis patients. JASN 1991; 2: 637 (a).

Brandi M.L. , Falchetti A. , Amorosi A. Use of a highly polymorphic locus on human chromosome 11_q 13 discloses allelic loss in parathyroid tissues from uremic patients. Bone and Mineral Metab 1991; 17: 69.

Frei U. , Klempa I. , Schneider M. , Scheuermann E.H. , Koch K.M. Tumor like growth of parathyroid autografts in uremic patients. Proceedings of the European Dialysis and Transplant Association 1981; 18: 548–53.

Korzets Z. , Magen H. , Kraus L. , Berheim J. , Bernheim J. Total parathyroidectomy with autotransplantation in haemodialysed patients with secondary hyperparathyroidism-should it be abandoned? Nephrol Dial Transplant 1987; 2: 341–6.

Kaye M. , D'Amour P. , Henderson J. Elective total parathyroidectomy without autotransplant in end-stage renal disease. Kidney International 1989; 35: 1390–9.

Kaye M. Parathyroid surgery in renal failure. A review. Seminars in Dialysis 1990; 3: 86–92.

Cohen-Solai M.E. , Sebert J.L. , Boudailliez B. Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreat-ment? Bone 1992; 13: 1–5.

Gagné E.R. , Urena P. , Leite-Silva S. Short and longterm efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. JASN (in press).